The new EANM paediatric dosage card: additional notes with respect to F-18

Introduction The previously published European Association of Nuclear Medicine (EANM) paediatric dosage card recommends 70 MBq F-18 or F-18 Fluoro-2-Deoxyglucose (F-18-FDG) as the "minimum recommended activity". Discussion Two recent publications demonstrate that when utilising F-18-labelled radiopharmaceuticals the administration of lower activities for small children is possible without losing image quality. Conclusion In the light of these findings the EANM dosimetry and paediatrics committee have decided to reduce the value for the "minimum recommended activity" for both F-18 and F-18-FDG to 26 MBq for 2D- and 14 MBq for 3D-acquisitions

Impact of F-18-fluciclovine PET/CT on Clinical Management of Patients with Recurrent Prostate Cancer: Results from the Phase 3 FALCON Trial

When biochemical recurrence (BCR) of prostate cancer is suspected, early and accurate localization of metastases facilitates treatment when tumors are small and most amenable to localized therapy, and may guide clinicians in making management plans regarding salvage therapy. Here, we present results of a preplanned analysis of the FALCON trial (NCT02578940), which assessed the impact of PET/CT imaging with 18F-fluciclovine on clinical management choices for men with BCR of prostate cancer